Close Menu

NEW YORK (GenomeWeb) – Vela Diagnostics has submitted a next-generation sequencing assay that detects HIV-1 drug resistance mutations (DRMs) to the US Food and Drug Administration, the company announced today.  

The Sentosa SQ HIV Genotyping Assay can be used on plasma samples from patients with HIV-1 infection to detect HIV-1 Group M genomic DRMs in the protease, reverse transcriptase, and integrase regions of the pol gene. Resistance to antiretroviral drugs as a result of DRMs is the most common cause of therapeutic failure in HIV treatment.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.